These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Kung YH; Wu TT; Huang YH Acta Ophthalmol; 2014 Dec; 92(8):e615-20. PubMed ID: 24924911 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Yoon JU; Byun YJ; Koh HJ Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012 [TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926 [TBL] [Abstract][Full Text] [Related]
7. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Wakabayashi T; Ikuno Y; Gomi F Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Lai TY; Chan WM; Liu DT; Lam DS Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555 [TBL] [Abstract][Full Text] [Related]
9. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP Retina; 2010; 30(10):1609-15. PubMed ID: 20856171 [TBL] [Abstract][Full Text] [Related]
10. FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION. Wu TT; Kung YH Retina; 2017 Nov; 37(11):2056-2061. PubMed ID: 28590318 [TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547 [TBL] [Abstract][Full Text] [Related]
12. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Parodi MB; Iacono P; Papayannis A; Sheth S; Bandello F Arch Ophthalmol; 2010 Apr; 128(4):437-42. PubMed ID: 20142520 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Chan WM; Lai TY; Liu DT; Lam DS Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414 [TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry. Gabrielle PH; Nguyen V; Creuzot-Garcher C; Miguel L; Alforja S; Sararols L; Casaroli-Marano RP; Zarranz-Ventura J; Gillies M; Arnold J; Barthelmes D Acta Ophthalmol; 2022 Feb; 100(1):e288-e296. PubMed ID: 33960115 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Peiretti E; Vinci M; Fossarello M Can J Ophthalmol; 2012 Feb; 47(1):28-33. PubMed ID: 22333848 [TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia. Wakabayashi T; Ikuno Y; Gomi F; Hamasaki T; Tano Y Am J Ophthalmol; 2009 Oct; 148(4):591-596.e1. PubMed ID: 19589497 [TBL] [Abstract][Full Text] [Related]
18. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519 [TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Lai TY; Luk FO; Lee GK; Lam DS Eye (Lond); 2012 Jul; 26(7):1004-11. PubMed ID: 22595908 [TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab for the treatment of choroidal neovascularizations associated with pathologic myopia: a prospective study. Pasyechnikova NV; Naumenko VO; Korol AR; Zadorozhnyy OS; Kustryn TB; Henrich PB Ophthalmologica; 2015; 233(1):2-7. PubMed ID: 25501802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]